Axon Enterprise, Inc. (AXON): what the price assumes

In the published model solve dated 2026-Q2, anchored at $601.47, Axon Enterprise, Inc. (AXON) is priced for today's economics sustained for ~28.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/AXON

Headline

FieldValue
TickerAXON
CompanyAxon Enterprise, Inc.
Sector / IndustryIndustrials
Current price$601.47/sh
CompositionTASER 33% / Personal Sensors 14% / Platform Solutions 10% / Software and Services 43%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Trailing margin (depressed year)0.7%
Must persist for28.3y
Multiple paid463x mid-cycle operating income

Solve inputs: computed at a 9.8% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

ReferenceValue
vs own history+0.65σ

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset12.17x1expensive
Earnings0
Relative0
Growth1.54x3expensive

Families that call it expensive: Asset, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=4)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$72.778.27xyesFCF base $0.3B, growth 25% (input: historical growth), terminal g 4.0%, WACC 9.0%, 7yr projection
DCF Exit MultipleGrowth$389.551.54xyesExit EV/EBITDA: 921.7x / 923.7x / 925.7x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelativenoP/E 39.6x (blended: static sector reference 18x + trailing (TTM) 245x), scenarios: 31.7x / 39.6x / 47.5x (bear / base = reference held flat / bull), EV/EBITDA 26.4x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$26.5222.68xyesBV/sh $45.23, ROE (TTM) 5.4%, ke 9.3% (excluded from median)
Two-Stage Excess ReturnAsset$19.3731.05xyes5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market CapGrowth$430.321.40xyesRev $3.2B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$0.0160146.50xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.06B × (1−10%) / WACC 9.0% → EPV (no growth) (excluded from median)
Residual IncomeAsset$18.5132.49xyesBV $45.23 + 5yr PV of (ROE (TTM) 5.4% − Kₑ 9.3%) × BV; BV grows 3.5%/yr (excluded from median)
Graham NumberAsset$49.4212.17xyes√(22.5 × EPS $2.40 × BVPS $45.23) — Graham's conservative floor
EV/EBITDA RelativeRelativenoEBITDA $0.05B × sector EV/EBITDA 12.0x
FCF YieldEarnings$3.68163.44xyesFCF $133.2M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$2.01299.24xyesEPS $2.40 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$4.41136.39xyesBV $45.23 × (ROIC 0.9% / WACC 9.0%) (excluded from median)
P/Sales SectorRelativenoRevenue $3.22B × sector P/S 2.5x
PEG Fair ValueRelativeno
Earnings YieldEarnings$25.9523.18xyesEPS $2.40 / required return 9.3% (Rf 4.3% + ERP 5.0%) (excluded from median)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Connected Devicesoperatingenterprise$1.6bwithheldunresolved no unit value
Software and Servicesoperatingenterprise$1.2bwithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$1.0b
Net debt / NOPAT (after-tax)10.87x
Net debt / operating income (pre-tax)9.78x
Interest coverage0.9x
Share count CAGR (dilution)3.4%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 3.3%); the trailing year was depressed.

Bullet Takeaways

Bull Case

Nothing conventional reaches this price. Value Axon on its book, on the profit it currently reports, on what the market pays for comparable revenue, or on discounted future cash flows, and every one of those approaches stops well short of $502.52. That is not a hidden signal. It is the market saying, openly, that the trailing income statement is the wrong object to value, and that the thing worth owning is a contracted revenue stream that has been signed but not yet recognized. Future contracted bookings reached $14.3 billion at the end of the March 2026 quarter, up 44% year over year, against annual revenue running near $3 billion. Roughly four years of revenue is already committed on paper.

What makes that stream unusual is what it is attached to. Software and Services is the largest of the four revenue lines at about 43%, with TASER at 33%, Personal Sensors at 14% and Platform Solutions at 10%. The 10-K describes the design intent: "Axon's products and services are designed to operate as an integrated ecosystem consisting of integrated connected hardware devices, cloud-hosted software applications and real-time operational tools." A department that buys the energy weapon ends up on the evidence platform; a department on the evidence platform ends up buying the cameras and the drones. The economics of the software half are the reward for that: the filing reports that "Adjusted gross margin for the Software and Services segment increased to 77.5% for the year ended December 31, 2025, compared to 76.8% for the year ended December 31, 2024. The increase was primarily driven by higher software mix."

Public-safety revenue also behaves better than its reputation. Municipal budgets sound precarious until you read how the accountants treat them: the 10-K states that "In contracts where the customer's performance is subject to budget appropriation clauses, consistent with historical experience we generally consider the likelihood of non-appropriation to be remote when determining the contract term and transaction price." Deferred revenue is the physical evidence, "composed mainly of unearned revenue related to our SaaS offerings, service-type extended warranties, stand-ready obligations to provide CED cartridges, rights to future CED, and rights to future hardware shipments in our subscription programs". Money collected in advance for things not yet delivered is the most honest form of demand there is.

Set the growth beside the incumbents and the gap is stark. MSI, named in Axon's own competition disclosure, carries $11.87 billion of revenue with a 24.7% operating margin and grew 8.3%; TYL, the closest public-sector software comparison, runs 15.5% and grew 8.7%. Axon grew 34% in the March 2026 quarter, its ninth consecutive quarter above 30%. Growing four times as fast as the entrenched supplier to the same buyer is the whole argument, and it is not a subtle one.

The fair objection is that none of this has yet arrived as reported profit. Cash is the counter-evidence: management guided 2026 operating cash flow above 600 million dollars, with free cash flow near 450 million dollars. The gap between that and the reported operating line is compensation paid in stock and amortization of past acquisitions, neither of which consumes cash in the year it is charged.

Bear Case

Strip the story down and the price depends on one specific belief: that city councils, county sheriffs and state agencies will keep funding thirty-percent annual increases in public-safety technology spending for decades. Not that the technology works, which it plainly does. That the appropriation keeps arriving. Axon's own filing names the failure mode without softening it, warning that "if agencies fail to appropriate funds in future year budgets, terminate contracts for convenience, or if other cancellation clauses are invoked, this would prevent us from recognizing anticipated revenue and cash flow". A contracted-bookings number is a schedule of intentions from customers whose budgets are voted on annually.

The second dependency is that the profit eventually shows up. Right now it does not. The trailing operating line converted about 0.6% of revenue, and the 10-K is direct about where the money goes, citing costs "primarily driven by higher stock-based compensation expense and acquired intangibles amortization" and describing a program that "includes grants of RSUs, PSUs, XSUs and stock options", with vesting tied to performance criteria measured at each balance-sheet date. Holders can see the bill in their own ownership: the share count has risen about 3.3% a year since 2022. Compensation paid in stock does not consume cash, which is the bull's point, and it does transfer part of the company to employees every year, which is the bear's.

Put a number on how much duration that requires and the demand becomes visible. On the company's through-the-cycle operating profit rather than the depressed trailing quarter, the price works out to roughly 446 times that figure, which implies operating profit compounding at the fastest rate Axon can fund from its own resources for something on the order of 27 years. Treat that as an approximation rather than a measurement, because with an operating line this thin the arithmetic is sensitive to small changes in the denominator. The historical reference is sturdier than that arithmetic: of comparable fast-growers, only about 14% sustained that pace even across a full decade. Twenty-seven is a different order of request.

There is also a governance detail that deserves more weight than it usually gets. Axon disclosed that "The Company did not design and maintain effective controls related to revenue recognition for its customer contracts." It has since acted, reporting that "During the fourth quarter of 2025, we completed the design and implementation of control activities" addressing the policies. For most companies a revenue-recognition control weakness is an inconvenience. For one whose entire investment case rests on multi-year contracts recognized across time, with judgment calls about contract term and transaction price at every step, it lands closer to the center of the thesis than the edge of it.

Finally, the balance sheet no longer offers a cushion. Net borrowings run near 994.0 million dollars on the funded-debt build, against gross borrowings of about 1.73 billion dollars, which works out to roughly 10.8 times operating profit measured through the cycle. Interest costs and the current operating line are about the same size. With free cash flow guided near 450 million dollars for 2026 this is manageable rather than dangerous, but it means a slowdown would be absorbed by holders rather than by a reserve.

Valuation

Start with why the standard toolkit fails here, because that fact is doing more work than any single number. Axon reports almost no operating profit, six-tenths of one percent of revenue over the trailing year. Any method that begins from earnings therefore begins from close to zero and ends up far below the current price, and the asset-based frames, which measure the company against its own book, land nearly as far away. The one approach that comes closest is the forward method that projects the revenue line and discounts what it should eventually produce, and even that stops short. Every family lands under $502.52. There is no internal disagreement to adjudicate, only a single unanimous statement that the price is not derived from the visible financials.

The peer frame is where the mismatch becomes legible. Priced against what the broad industrial sector pays for a dollar of sales, Axon looks extravagant. Priced against the software companies it actually competes with for the same buyer, less so, but the comparison cuts both ways. MSI converts 24.7% of $11.87 billion of revenue into operating profit; TYL converts 15.5%; PLTR, the most profitable software name in the cohort, converts 38.1%. Axon has software-like gross profitability, evidenced by the filing's report that "Adjusted gross margin for the Software and Services segment increased to 77.5% for the year ended December 31, 2025", and hardware-company operating profitability. The entire valuation question is whether the first eventually pulls the second up to it.

Reading the price backwards puts a rough scale on the wait. Against through-the-cycle operating profit rather than the trailing figure, the price works out near 446 times that number, which corresponds to operating profit growing at Axon's self-funding ceiling for roughly 27 years. That solve deserves to be held loosely: when the denominator is this small, modest changes to it swing the implied horizon substantially. The more robust observation sits beside it. Among comparable fast-growers, roughly 14% held that pace across a full decade, and the near-term rate the price asks for is inside what Axon has recently delivered. The stretch is duration, not speed.

What underwrites the wait is the contracted book rather than the balance sheet. Deferred revenue is real: the filing describes it as "unearned revenue related to our SaaS offerings, service-type extended warranties, stand-ready obligations to provide CED cartridges, rights to future CED, and rights to future hardware shipments in our subscription programs", money already collected against future delivery. Borrowings are a secondary consideration at roughly 10.8 times operating profit on a through-the-cycle basis, with 2026 free cash flow guided near 450 million dollars. The share count, rising about 3.3% a year, is the more consequential line, because each year's grants dilute the eventual profit the price has already paid for.

Catalysts

The March 2026 quarter, reported May 6, 2026, kept the streak intact. Revenue came in at $807 million, up 34% year over year, and net income at $169 million; it was the ninth consecutive quarter in which revenue grew more than 30%. The number that matters more for a subscription business landed alongside it: future contracted bookings of $14.3 billion, up 44% from a year earlier, which is the pipeline of revenue already signed and scheduled rather than forecast.

Management raised the year on the strength of it, moving the 2026 revenue growth outlook to a range of 30% to 32% from 27% to 30%, and guiding operating cash flow above 600 million dollars with free cash flow near 450 million dollars. Raising a growth range this late into a run of thirty-percent quarters is a specific claim about demand rather than a general expression of confidence, and the artificial-intelligence products inside the software line were named as the driver.

Two things worth tracking through the rest of the year sit outside the headline. The first is the revenue-recognition control remediation, which the 10-K says was designed and implemented during the fourth quarter of 2025; the next annual assessment is where its effectiveness gets tested. The second is mix. Software and Services is already the largest revenue line, and the rate at which it keeps taking share from hardware inside the total is the mechanism by which reported profit would eventually catch up to the cash the business is generating.

Peer Cohorts (Per Segment, With Filing Citations)

Connected Devices (reported)

Software and Services (reported)

Article Insight (Recent News Sentiment)

Sentiment score: 75.00 (HIGH confidence) FUD/Hype: HYPE_DETECTED (The articles consistently emphasize bullish analyst ratings and growth potential, bordering on promotional language.) Claim alignment: ALIGNED

These articles collectively signal positive sentiment regarding Axon Enterprise, primarily driven by analyst upgrades and enthusiasm surrounding its AI-powered product suite.

The Globe and Mail

Insider Monkey (AI Co-Pilot)

Insider Monkey (Growth Metrics)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Axon Q1 2026 results, May 6, 2026 · Axon 2026 outlook, May 6, 2026

View the full interactive AXON report on boothcheck